# US drug agency approves breakthrough pancreatic cancer treatment

https://mins.news/en/item/33642

- BBC News, 2026-08-26 22:02 UTC
- Health
- Original: https://www.bbc.co.uk/news/articles/clyq4ge4wk9o?at_medium=RSS&at_campaign=rss

> The US Food and Drug Administration has approved daraxonrasib, sold as Rasonque, for pancreatic cancer. In a 500-patient late-stage trial, average survival was 13.2 months for people taking the daily pill, compared with 6.6 months for chemotherapy. The drug targets mutated KRAS, which drives tumour growth.

## Related coverage

- [FDA approves breakthrough pancreatic cancer treatment](https://mins.news/en/video/33720) — NBC News, 2026-08-26
- [FDA approves Rasonque for advanced pancreatic cancer](https://mins.news/en/item/33694) — France 24, 2026-08-26
- [Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment](https://mins.news/en/item/33472) — Bloomberg News, 2026-08-26